Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

About this Publication
Title
The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise.
Pubmed ID
15283897 (View this publication on the PubMed website)
Publication
Urol. Oncol. 2004; Volume 22 (Issue 4): Pages 358-61
Authors

Andriole GL, Reding D, Hayes RB, Prorok PC, Gohagan JK, PLCO Steering Committee

Abstract

The Prostate, Lung, Cancer, and Ovarian Cancer Screening Trial is a randomized, multicenter, study evaluating whether screening for prostate, lung, colon, and ovarian cancer will reduce cancer-specific mortality. More than 155,000 participants have been identified and will be monitored through 2015. A biorepository of screened individuals and control participants has been created. Together, the data derived from the intervention and control arms and material in the biorepository provide a valuable resource to allow identification and testing of novel biomarkers for human disease.

Related CDAS Studies